key: cord-0722535-dc9ee7qz
authors: Lambert-Niclot, Sidonie; Cuffel, Alexis; Le Pape, Samuel; Vauloup-Fellous, Christelle; Morand-Joubert, Laurence; Roque-Afonso, Anne-Marie; Le Goff, Jérôme; Delaugerre, Constance
title: Evaluation of a Rapid Diagnostic Assay for Detection of SARS-CoV-2 Antigen in Nasopharyngeal Swabs
date: 2020-07-23
journal: J Clin Microbiol
DOI: 10.1128/jcm.00977-20
sha: 4f7daa40eaef26261a50cfc56460a8727bf698e4
doc_id: 722535
cord_uid: dc9ee7qz

Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), the virus causing causing Coronavirus disease 2019 (COVID-19) was reported for the first time in Wuhan (Hubei, China) in December 2019 (1, 2) and has become a major public health concern all over the world.….

S evere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing coronavirus disease 2019 (COVID-19), was reported for the first time in Wuhan (Hubei Province, China) in December 2019 (1, 2) and has become a major public health concern all over the world. Early diagnosis is crucial for patient management and outbreak control. Most tests currently used for the detection of SARS-CoV-2 rely on viral RNA amplification by using real-time PCR (RT-PCR) and require a few hours before result release. Hence, highly sensitive immunological diagnostic methods that directly detect viral antigens in clinical samples would be very helpful for rapid and accurate diagnosis of COVID-19.

Here, we evaluated a rapid diagnostic test, COVID-19 Ag Respi-Strip (Coris Bio-Concept, Gembloux, Belgium), for detection of the SARS-CoV-2 antigen in nasopharyngeal secretions. The assay is ready to use and based on a nitrocellulose membrane technology with colloidal gold nanoparticles sensitized with monoclonal antibodies directed against highly conserved SARS-CoV-2 nucleoprotein antigens. We compared this test with RT-PCR, the current reference assay in virology laboratories of three university hospital groups from Assistance-Publique-Hôpitaux de Paris (APHP) (Saint-Antoine-Tenon-Trousseau, Saint-Louis-Lariboisière, and Kremlin Bicêtre-Paul Brousse). In our study, the COVID-19 Ag Respi-Strip (Coris) had a sensitivity of 50% compare to that of RT-PCR. The test was more sensitive for high viral loads and might perhaps be used for patients within a few days after symptom onset, when the load in the upper respiratory tract is at its peak. Considering COVID-19's current low prevalence of 0.19% in France, prospective studies should be conducted to determine the best settings for its implementation.

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

China Novel Coronavirus Investigating and Research Team. 2020. A novel coronavirus from patients with pneumonia in China

Development and potential usefulness of the COVID-19 Ag Respi-Strip diagnostic assay in a pandemic context

All cycle threshold values of E gene real-time PCR-positive assays are shown for positive and negative COVID-19 Ag Respi-Strip assay results. Results gathering C T values for all real-time PCR-positive assays are depicted by squares. C T values between samples positive or negative for the antigenic assay are significantly different (* indicates a P value of Ͻ0.0001). C T values corresponding to the Cobas 6800